Theravance Biopharma TBPH Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Theravance Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's interest expense?
- Theravance Biopharma (TBPH) reported interest expense of $582K in Q4 2025.
- How has Theravance Biopharma's interest expense changed year-over-year?
- Theravance Biopharma's interest expense decreased by 9.5% year-over-year, from $643K to $582K.
- What is the long-term trend for Theravance Biopharma's interest expense?
- Over 4 years (2021 to 2025), Theravance Biopharma's interest expense has grown at a -45.4% compound annual growth rate (CAGR), from $27.76M to $2.46M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.